As the global economy mends, the 2021 growth of Leuprolide will have significant change from previous year. According to our (LP Information) latest study, the global Leuprolide market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Leuprolide market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Leuprolide market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Leuprolide market, reaching US$ million by the year 2028. As for the Europe Leuprolide landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Leuprolide players cover TOLMAR PHARMACEUTICALS, Sanofi, Teva, and Sandoz (Novartis), etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Leuprolide market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Subcutaneous
Topical
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Breast Cancer
Endometriosis
Precocious Puberty
Prostate Cancer
Uterine Fibrosis
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
TOLMAR PHARMACEUTICALS
Sanofi
Teva
Sandoz (Novartis)
Sun Pharmaceutical
AbbVie
Bayer
Takeda
Beijing Boente Pharmaceutical
Livzon Pharmaceutical
Selleck
Hangzhou Peptide Biochemical
Chengdu Shenguo Biological Pharmaceutical
SciAnda Pharma
Daewoong
GP Pharm
Enteris BioPharma
Chong Kun Dang
Leadiant Biosciences
Hikma Pharmaceuticals
Lee Pharma
Hanall